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ABSTRACT
Circulating Tumour Cells (CTCs) are promising cancer biomarkers. Several
methods have been developed to isolate CTCs from blood samples. However, the
isolation of melanoma CTCs is very challenging as a result of their extraordinary
heterogeneity, which has hindered their biological and clinical study. Thus, methods
that isolate CTCs based on their physical properties, rather than surface marker
expression, such as microfluidic devices, are greatly needed in melanoma. Here, we
assessed the ability of the slanted spiral microfluidic device to isolate melanoma CTCs
via label-free enrichment. We demonstrated that this device yields recovery rates of
spiked melanoma cells of over 80% and 55%, after one or two rounds of enrichment,
respectively. Concurrently, a two to three log reduction of white blood cells was
achieved with one or two rounds of enrichment, respectively. We characterised the
isolated CTCs using multimarker flow cytometry, immunocytochemistry and gene
expression. The results demonstrated that CTCs from metastatic melanoma patients
were highly heterogeneous and commonly expressed stem-like markers such as PAX3
and ABCB5. The implementation of the slanted microfluidic device for melanoma CTC
isolation enables further understanding of the biology of melanoma metastasis for
biomarker development and to inform future treatment approaches.

survival in the first year after diagnosis [1, 2]. Despite
remarkable advances in the treatment of melanoma, only
20% of patients with metastatic spread show long lasting
responses (>2 years) to current treatments [3–6]. Thus,

INTRODUCTION
Metastatic disease occurs in approximately 10% of
melanoma patients at diagnosis and drastically reduces
www.impactjournals.com/oncotarget
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a better understanding of the pathogenic mechanisms
underlying metastatic spread will ultimately lead to the
discovery of biomarkers that predict, with high reliability,
clinical outcome and treatment response, a critical unmet
need for melanoma.
Circulating tumour cells (CTCs), are the tumour
seeds responsible for metastatic haematogenous
dissemination of solid tumours and arise from both
primary and secondary tumours. Since CTCs can be
detected and isolated from blood, phenotypic and
genetic characterisation of these cells provides insightful
information about the biology of melanoma metastasis,
as well as the evolving phenotype and genotype of all
concurrent tumours within a patient [7]. The ease of access
of CTCs from blood for repeated sampling, exemplifies
CTCs as invaluable biomarkers for real-time monitoring
of clinical status and treatment response [8, 9]. In
melanoma, cumulative evidence supports a role for CTCs
in the prediction of clinical outcome and monitoring of
therapeutic response [10–14].
Despite the potential biomarker utility of CTCs,
the isolation and detection of these cells is a significant
technical challenge that must be overcome to achieve
a better understanding of their biology and role in
metastasis, as well as for their implementation in the
clinic. Firstly, CTCs are extremely rare in the blood of
melanoma patients (i.e. 1-10 cells per 8 mL of blood)
[10–12, 15–17], demanding methods that isolate CTCs
at a high recovery rate and with a low background of
white blood cells (WBCs). Secondly, the high phenotypic
heterogeneity observed in melanoma CTCs adds
significant complexity, with no single marker detecting the
majority of melanoma CTCs [10, 13, 15, 16, 18]. This is in
contrast with the use of the cell surface marker, EpCAM
(epithelial cell adhesion molecule) [19] and the internal
marker, cytokeratin, standard CTC markers for epithelial
cancer cells [20–23]. Thus, conventional isolation methods
that depend on the expression of cell surface markers (i.e.
label-dependent methods) are not optimal in melanoma
and provide a biased isolation outcome [7]. Instead, labelindependent isolation methods (i.e. microfluidic devices)
may provide a solution, as they utilise differential cell
size, density and rigidity to enrich CTCs from blood [18,
24–27]. Various microfluidic devices have been developed
and validated for isolation of CTCs from patients with
different types of cancer, mainly of epithelial origin,
such as micro-fabricated filters [28, 29], electric-based
approaches [30], the herringbone CTC-Chip [31], CTCiChip [32], Cluster-Chip [18], Parsortix [26, 33] and
spiral-based chips [24, 34].
In melanoma, microfluidic devices (i.e. herringbone
CTC-Chip, CTC-iChip or Cluster-Chip) have been used
to isolate single or cluster CTCs from metastatic patients
before [13, 18, 32] and during treatment with MAPK
inhibitors [13]. However, additional isolation methods
that yield a viable, label-free and more diverse fraction of
www.impactjournals.com/oncotarget

CTCs are urgently required for the isolation of melanoma
CTCs. The implementation of such methods in melanoma
is also critical for downstream applications, such as
genetic and phenotypic characterisation of CTCs, cell
culture and CTC-derived xenotransplantion, which will
provide an insight into the biology of CTCs and melanoma
metastasis [18, 35–38].
Spiral microfluidic devices, which rely on “Dean
drag” forces, have been recently developed to isolate
CTCs based on cell size, deformability and density
with high purity, viability and recovery efficiency [24,
34, 39]. These spiral devices have demonstrated their
superiority over the only FDA-approved platform for CTC
enumeration, CellSearch® (Janssen Diagnostics LLC), in
the recovery of CTCs in breast and lung cancer patients
[34]. Particularly, the slanted spiral device has been shown
to yield recovery rates of over 80% with spiked breast and
bladder cancer cells, and to isolate and detect CTCs in
almost all the analysed blood samples from patients with
metastatic breast and lung cancer [24]. But no report has
been shown its utility for the isolation of melanoma CTCs.
This device has the advantageous capability of being able
to process 8 mL of blood sample in less than 10 minutes to
yield CTCs at relatively high purity (500 WBCs per mL of
processed blood) [24], compared to over an hour by other
microfluidic devices [18, 25, 31–33, 39]. In addition, short
term cell cultures of CTCs from breast cancer patients
have been established after isolation of CTCs through this
slanted device, demonstrating the high viability of CTCs
isolated through this device, as a result of the low shear
stress caused to the cells [38].
Here, we validate the ability of the slanted spiral
microfluidic device to isolate a viable, label-free and
heterogeneous population of CTCs from the blood of
melanoma patients with metastatic disease. Furthermore,
this enrichment allowed us to interrogate the phenotype
and gene expression profile of CTCs isolated from
metastatic melanoma patients prior to treatment, using
multimarker flow cytometry, gene expression analysis and
immunofluorescence staining.

RESULTS
Recovery and purity of melanoma cells with
different cell size
To determine the efficiency of the slanted spiral
microfluidic device to isolate circulating melanoma cells
of different cell sizes, we firstly classified the melanoma
cell lines 1205Lu, A2058, SKMEL5, UACC62, WM164
and WM793, based on their cell size, inferred by forward
scatter values in a flow cytometer platform (Supplementary
Figure 2). A2058 and SKMEL5 were respectively
identified as the cell lines with the smallest (mean cell
diameter: 14 μm) and largest cell size (mean cell diameter:
18 μm), and the mean cell diameters significantly differed
2
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between these two melanoma cell lines (P=0.0002) (Figure
1A). We spiked blood from healthy individuals with
increasing amounts of these cell lines and processed them
through the slanted spiral microfluidic device. An overall
average recovery rate of 83% was observed across all
the spiked blood samples with either A2058 or SKMEL5
cells, and no significant differences were observed in the
recovery rates for each melanoma cell line, regardless
of the number of cells spiked (Figure 1B). To assess the
purity of the enriched fraction, we quantified WBCs in the
sample before and after processing through the slanted
device. We achieved a 2 log reduction in the number of
WBCs after processing the sample once (1X slanted)
through this device (mean: 2.0 x 105; range: 0.7 - 4.2 x
105) compared to the initial WBC count (mean: 1.5 x 107,
range: 1.2 - 1.7 x 107) (Figure 1C).
A second slanted enrichment was performed (2X
slanted) with the purpose of further reducing the WBC
background for future genetic interrogation of the CTC
fraction. This resulted in a total 3 log WBC reduction
(mean: 1 x 104; range: 0.7-4 x 104) after 2X slanted
enrichment (Figure 1C). We measured the recovery rates
of the 2X slanted enrichment by spiking 50 A2058 or
SKMEL5 cells into healthy donor blood to determine
whether a second slanted enrichment could yield an
enriched sample with a higher purity without loss in
recovery of melanoma cells. We obtained an average
recovery rate of 74% for A2058 and 55% for SKMEL5
cells (Figure 1D).
Next we proceeded to analyse CTCs in melanoma
patient blood samples, firstly assessing the purity and
secondly identifying CTCs in the CTC-enriched samples
after slanted enrichment. To determine the level of purity
of CTC fractions from patients after enrichment with the
slanted spiral device, we counted WBCs before and after
processing 8 mL of blood from 5 metastatic melanoma
patients once and twice through the slanted spiral device.
On average, we again found a 2-3 log reduction in WBCs
relative to the initial WBC count (mean: 3.5 x 107 WBCs
(range: 2.4 x 107 - 4.9 x 107), after 1X slanted, 7.7 x 105
WBCs (range: 245,000 – 465,500) and after 2X slanted,
8.6 x 104 WBCs (range: 49,105 – 123,203). Thus, a
second round of enrichment through the slanted device
demonstrated its ability to significantly deplete WBCs
with high significance in both control and patient samples
(P<0.0001), even though WBC levels were higher in
patients than in healthy controls (Figure 1C). Samples
from these 5 patients were included in the CTC detection
experiments detailed below.

metastatic melanoma patients, prior to treatment (baseline)
(Table 1). The ‘CTC fraction’ was stained with multiple
markers and analysed by flow cytometry, as previously
described by Gray et al. [10]. Results were compared to
the number of CTCs observed in a separate sample from
each patient without slanted enrichment but analysed
by flow cytometry. This flow cytometry assay identifies
subpopulations of CTCs based on their positivity for
melanoma-associated markers, MCAM (melanoma cell
adhesion molecule) and MCSP (melanoma-associated
chondroitin sulphate proteoglycan), and/or their positivity
for melanoma-initiating cell markers, ABCB5 (ATPbinding cassette subfamily B member 5), CD271 and
RANK (Receptor Activator of NFkβ pathway) [10].
Using this approach, we detected CTCs in 7 out of
10 patients, with a median of 5 CTCs (range: 1 - 565)
in 8 mL of blood, before any slanted enrichment. As
previously described [10], we observed high diversity in
the phenotype of CTCs detected in these patients before
slanted enrichment. ABCB5 was the most common marker
of CTCs, and RANK was the second most common
marker, expressed either alone or in combination with
ABCB5. Melanoma-associated markers MCSP and
MCAM were not detected on any CTCs isolated from
the 10 metastatic melanoma patients (Figure 2). We also
detected CTCs post slanted enrichment in 4 out the 7
CTC positive patients, though at lower numbers (1-62
CTCs) (Figure 2). The 6 cases with no CTCs detected
after processing through the microfluidic device had low
or no CTC counts (0-6 CTCs) prior to any enrichment. In
contrast, cases with detected CTCs after slanted processing
had much higher initial CTC counts (24-565 CTCs in
8 mL of blood). The phenotype of the cells isolated by
the slanted device were present prior to enrichment,
albeit at different frequencies. The melanoma-initiating
marker ABCB5 remained the most common marker after
slanted enrichment and was observed to be more highly
represented after enrichment than the other CTC markers.

Molecular detection of melanoma-specific
transcript levels in enriched fractions
We also characterised the melanoma cells in the
‘CTC fraction’ after slanted enrichment by assessing the
gene expression of 5 melanoma-associated genes [40].
The genes included: MLANA/MART1 (melanoma antigen
recognized by T cells), TYR (tyrosinase), MAGEA3
(melanoma antigen family A3), PAX3 (paired box
protein Pax-3 isoform 3) and ABCB5. These genes were
selected based on their known exclusive expression in
melanoma cells and their undetected expression by this
RT-PCR assay in WBC samples from healthy individuals
(n=5). Moreover, these genes are either known markers
of melanoma pathology, due to their high expression
in melanoma tumours, and/or involved in melanoma
pathogenesis [41–44].

Detection of CTCs by flow cytometry before and
after slanted enrichment
In order to demonstrate the presence of melanoma
cells in the ‘CTC fraction’ after enrichment through the
slanted spiral device, we processed blood samples from 10
www.impactjournals.com/oncotarget
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First we assessed whether we can detect these 5
genes in RNA extracted from samples containing 1, 5,
10 and 20 melanoma cells spiked into 100,000 WBCs,
the level of WBC background observed after 2X slanted
enrichment (Figure 1C). Transcripts of MLANA, TYR,
MAGEA3, PAX3, and ABCB5 were successfully identified
from a single melanoma cell, as reflected by the increase
in reciprocal Ct values (1/Ct) (Figure 3).
In patient samples, we detected melanoma specific
transcripts in 7 out of 13 (54%) CTC enriched fractions
from metastatic melanoma patients. In particular, the PAX3
transcripts were detected exclusively in 3 out of the 7
positive CTC-enriched samples, while also detected along
with ABCB5 in another 2 cases (thus 5/7 cases). ABCB5
and MLANA transcripts were detected alone in one patient
each (Figure 3). Differences in 18S rRNA Ct values
across all analysed samples were a result of differential
WBC counts in the CTC fractions across all patients.
Interestingly, all the 7 patients with detected PAX3,

ABCB5 or MLANA transcripts by RT-PCR had metastatic
disease in distant organs (stage M1c) and two of three
cases with brain metastases had CTC fractions positive
by RT-PCR, for MLANA and PAX3. Furthermore, four of
the patients with detected melanoma-specific transcripts
had CTC counts higher than 155 CTCs per 8 mL of blood;
whilst the remaining three had from 1 to 11 CTCs per 8
mL of blood, detected by flow cytometry before slanted
enrichment. In contrast, the patients with undetected
transcripts had at least 1 CTC per 8 mL of blood (n= 5,
1-81 CTCs) detected by flow cytometry before slanted
enrichment, with only one case negative for CTCs.

Detection of melanoma CTCs using
immunostaining
To further demonstrate the presence of CTCs
in the enriched fractions, we developed a melanomaspecific multimarker immunostaining protocol. Markers

Figure 1: Recovery rates and purity of melanoma cells isolated using a slanted spiral microfluidic device. Melanoma

cells were spiked into blood from healthy donors. (A) Comparison of the mean diameters of melanoma cell lines A2058 and SKMEL5,
after five consecutive passages, yielded a statistically significant difference between mean diameters of both cell lines (t-test, P=0.0002).
(B) Recovery rates of 5, 10, 50 and 100 CellTracker™ red-labelled A2058 and SKMEL5 cells spiked in blood from healthy donors after 1X
slanted enrichment (n=3). No statistically significant differences were found in the recovery rates for A2058 (P=0.376) and SKMEL5 cell
lines (P=0.102) between different spiked amounts. (C) WBC counts in the blood of healthy donors (controls, n=3) and metastatic melanoma
patients (n=5) before and after the first and second round of enrichment with the slanted microfluidic device. A one-way ANOVA analysis
determined a highly significant depletion of WBCs after the second round of enrichment with the slanted device in both controls (P<0.0001)
and patients (P<0.0001). (D) Recovery rates of 50 A2058 and SKMEL5 cells spiked into blood after two rounds of slanted enrichment
(controls, n=4). Error bars represent one standard deviation from the mean values across replicates.
www.impactjournals.com/oncotarget
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Table 1: Demographic and clinical information of metastatic melanoma patients
Characteristic

n

Total patients enrolled

20

% of total

Age at enrolment (years)
Median

66

Range

34 - 80

Gender
Male

13

65%

Female

7

35%

4

20%

M1b

1

5%

M1c

15

75%

V600E

11

55%

V600R

1

5%

V600K

1

5%

1

5%

6

30%

Pembrolizumab

10

50%

Dabrafenib + Trametinib

10

50%

Stage of disease at baseline
Stage IV
M1a
α

Mutational status of
tumour
BRAF

Other BRAF*
Wildtype BRAF

+

Prior treatment for
(Baseline):

* Case with BRAF N581S, NRAS G12D, MET E355K mutations. + Case with wild type status for BRAF and NRAS, but
with KIT L576P and CTNNB1 S37F mutations. α Three cases with brain metastases.
included MCSP, a melanoma cell surface specific marker,
together with a mixture of internal melanocytic markers,
gp100 (glycoprotein 100), S100, and MLANA, hereafter
called “MEL” immunostaining. Firstly, we optimised this
staining in A2058 cells spiked into WBCs from healthy
volunteers (Figure 4A). Subsequently, we used this
immunostaining protocol to detect melanoma CTCs in
enriched fractions isolated from 7 metastatic melanoma
patients using the slanted spiral device. Using this staining
protocol, we observed CTCs in 3 cases (43%), with 1, 3
and 4 CTCs in 8 mL of blood. All detected CTCs were
positive for the combination of intracellular markers
“MEL” but negative for MCSP staining and exhibited an
average cell size of 16 μm (range: 13 – 21 μm) (Figure
4B). Furthermore, two of the 3 cases with detected
CTCs by immunostaining had melanoma metastasis in
www.impactjournals.com/oncotarget

distant organs (stage M1c), and the remaining one had
subcutaneous and lymph node metastases.

DISCUSSION
The isolation of CTCs is critical for the study of the
role of these cells in the metastatic process as well as their
utility as biomarkers in the clinical management of cancer.
Therefore, the implementation of methods that enable the
isolation of viable and label-free CTCs is of high biological
and clinical significance. This is particularly important for
isolation of CTCs from melanoma patients due to their
diversity, since label-based capture significantly biases the
number of CTCs that can be identified [10, 15, 16]. Here,
we report the successful isolation of CTCs from the blood
of metastatic melanoma patients using a slanted spiral
5
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microfluidic device. We demonstrate, through downstream
interrogation of the CTC phenotype by flow cytometry,
immunostaining and gene expression analyses, that labelfree enrichment of melanoma CTCs successfully isolates
heterogeneous subpopulations of cells.
The slanted spiral microfluidic device enabled
us to retrieve melanoma cells with different cell sizes
with a recovery rate similar to that observed for breast
and bladder cancer cell lines [24]. This demonstrates
the reliability of this device to differentially enrich for
cancer cells regardless of cell size and cancer type; a very
important feature in further applications of this device.
In addition, we achieved close to a 3 log reduction of
WBCs after a second round of slanted enrichment without
markedly affecting enrichment efficiency. Despite a
reduction of 2-3 log fold of WBCs in healthy donors and
patients after one or two rounds of slanted enrichment,
a higher leukocytic background was observed than
that previously reported at 5 x 103 WBCs per 8 mL of
processed sample after 1X slanted enrichment [24]. A
higher leukocytic background in the CTC fraction in
patient samples relative to controls is likely due to the
observed leukocytosis exhibited by metastatic melanoma
patients [45]. Further strategies, such as CD45 depletion
[27] might better reduce the number of leukocytes after
slanted enrichment for further molecular and genomic
characterisation of melanoma CTCs. However, despite the
need to further improve the leukocytic background yielded

by the slanted device in controls (10,000 WBCs per 8 mL
of blood) and patients (86,000 WBCs per 8 mL of blood),
these values are better than those reported for CTC-iChip
(32,000 WBCs per mL of control blood), which was
previously used for isolation of melanoma CTCs [46].
More recent microfluidic platforms, such as Parsortix
(Angle plc), have shown promising results in regards to
WBC depletion, with approximately 2800 WBCs detected
after processing 4 mL of blood from healthy volunteers
[33]. Therefore, a study comparing the recovery, WBC
depletion in patients and CTC isolation efficiencies, for
melanoma, of the slanted spiral microfluidic relative
to other microfluidic devices [18, 26, 32] is strongly
encouraged. This approach will determine the best
platform for melanoma CTC isolation to be utilised in
further clinical studies. Nonetheless, the microfluidic
platforms previously used for isolation of melanoma
CTCs are not readily available [13, 18, 32].
Phenotypic analysis of CTCs before and after
slanted enrichment, using multimarker flow cytometry
[10], showed reduction in the number and diversity of
CTCs being enriched by the slanted spiral microfluidic
device. This is mainly caused by a preferential enrichment
of CTCs expressing ABCB5 over the rest of the melanoma
CTCs expressing other markers, particularly RANK
expressing CTCs. Since the slanted spiral device isolates
CTCs based on their differential cell size and density [24],
it is possible that ABCB5+ cells vary in these physical

Figure 2: Diversity of melanoma CTCs pre and post slanted enrichment. Comparison of phenotype and number of CTCs

identified before and after slanted enrichment in 10 metastatic melanoma patients using multimarker flow cytometry. Bars indicate the
number of CTCs detected by flow cytometry in each individual, with each phenotype indicated by a colour and pattern.
www.impactjournals.com/oncotarget
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Figure 3: Gene expression of 5 melanoma-specific genes in samples from healthy controls, spiked samples and CTC
fractions from metastatic melanoma patients after slanted enrichment. Heatmap represents the expression levels of the
melanoma-associated genes MLANA, TYR, MAGEA, ABCB5 and PAX3, which were assessed by RT-PCR. The 18S rRNA gene was used
as an endogenous control. Cellular fractions after slanted processing of the blood from 5 healthy controls were used as negative controls.
Spiked samples with 1, 5, 10 and 20 A2058 melanoma cells in a background of 1 x 105 WBCs were used to demonstrate the detection level
of this assay. CTC-enriched fractions from 13 metastatic melanomas were interrogated. Spiked samples with 20 A2058 cells were used as
positive controls in every run. Each heatmap square corresponds to the reciprocal value of the Ct values for each target gene (1/Ct) for a
given sample.
www.impactjournals.com/oncotarget
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characteristics and might be preferentially enriched.
Ozkumur et al. [46] have indicated a variability of
melanoma CTCs in cell size after microfluidic isolation,
but it is still unclear whether CTC subtypes do in fact
vary in cell size and density. The differential recovery
rates observed for the melanoma cell lines A2058 and
SKMEL5 after a second round of slanted might support
this preferential enrichment. It is possible that these cell
lines may not only differ in size but also in other physical
properties such as cell density or deformability, explaining
the differential recovery observed. Nevertheless, despite
the reduction in number and diversity of melanoma CTCs
after slanted enrichment, we did obtain a heterogeneous
fraction of CTCs, identified by another two independent
methods, melanoma-specific gene expression assays and
immunofluorescent staining.
Our immunocytochemistry staining protocol
identified CTCs expressing melanocytic markers in 43%
of metastatic melanoma patients. However, this method
would miss cells expressing melanoma-initiating markers.
The evidence that a vast majority of melanoma CTCs
express “stem cell” markers such as ABCB5, shown by
flow cytometry and PAX3, by gene expression, argues for
inclusion of such markers to increase the CTC detection
rate by immunocytochemistry.
The most significant finding from this study is the
detection of the expression of melanoma-specific genes
in CTC fractions after slanted enrichment. We found
melanoma-associated gene expression in 54% of analysed

CTC fractions. All patients with CTCs positive by RTPCR for PAX3, ABCB5 or MLANA transcripts exhibited
metastatic disease in distant organs (M1c) prior to
treatment and two of the three cases with brain metastases
were positive for PAX3 or MLANA. Interestingly, the fact
that PAX3 and ABCB5 were detected in 6 out 7 cases
with metastatic disease, positive by RT-PCR, might
provide further evidence supporting the role of these
genes in melanoma progression [14, 44, 47–50], but more
importantly in the biology of melanoma CTCs. Thus,
while this study was not aimed at determining a correlation
between the expression of these melanoma-specific genes
and clinical indicators, such as tumour burden or location,
our findings warrant confirmation in a larger cohort.
Interestingly, PAX3 transcripts were detected in five
out of the seven CTC positive cases, being co-expressed
with ABCB5 in two of those. The specific role of PAX3
in the biology of melanoma CTCs requires further
investigation. PAX3 is a transcription factor that directs
melanocytic differentiation from neural crest cells, and
is involved in stem cell maintenance and cell migration
of melanoblasts [51–54]. PAX3 is also highly expressed
in primary and secondary melanoma tumours [47, 49].
It is possible that PAX3 might orchestrate melanoma
metastasis by maintenance of the “stem cell” phenotype of
these cells during migration [47, 51, 53, 54]. In addition,
PAX3 has been described as a mediator of a drug-tolerance
phase prior to the development of acquired resistance to
targeted MAPK inhibition, via upregulation of MITF [55].

Figure 4: Melanoma-specific multimarker immunofluorescence staining for detection of melanoma CTCs. (A)

Optimisation of immunostaining protocol in WBC samples spiked with A2058 cells, cytospun onto glass slides, fixed, permeabilised and
immunostained with a combination of cell surface, MCSP (Alexa Fluor® 647, purple), and intracellular -MEL- (gp100, S100 and MLANA;
Alexa Fluor® 488, green) markers. DAPI was used for nuclei staining and CD45 (PE, red) as a leukocytic marker. Differential expression of
MCSP and MEL markers was observed in A2058 cells. (B) Representative melanoma CTCs detected by this immunofluorescence staining
in metastatic melanoma patient blood processed twice through the slanted spiral microfluidic device. Melanoma CTCs had an average cell
size of 16 μm (range: 13 – 21 μm). MCSP staining was not detected in any of the isolated melanoma CTCs from patient samples. Scale bar
represents size of the cell in μm.
www.impactjournals.com/oncotarget
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Thus, the detection of PAX3 in CTC fractions might also
have clinical implications. In this study, PAX3 transcripts
were detected in two out of ten patients prior to MAPK
treatment, and three out of ten pembrolizumab patients.
Further study of the relationship between PAX3 expression
in melanoma CTCs with early response to MAPK
inhibitors, in a larger cohort of patients, may provide an
insight into its role in the development of acquired
resistance and its biomarker utility.
ABCB5, a tumour initiating or “stem cell”
marker known to be involved in tumour resistance to
chemotherapy and targeted therapy in melanoma, identifies
a subset of slow-cycling tumour cells with increased
potential to initiate metastases [44, 50, 56]. Previously,
we reported [14] the expression of ABCB5 in unenriched
whole blood from melanoma patients by RT-PCR and
showed that ABCB5 transcripts were present in 40% of
melanoma cases at all stages, particularly in those with
disease recurrence (49%) and metastatic disease (52%).
Here we found ABCB5 gene expression detected by RTPCR in 23% of all CTC-enriched patient samples with no
detection of ABCB5 transcripts in ‘CTC fractions’ from
healthy donors. ABCB5 was also found to be the most
commonly expressed marker by melanoma CTCs detected
by flow cytometry in unenriched and enriched samples.
These findings highlight the importance of ABCB5 in
CTC biology and the intrinsic heterogeneous nature of
melanoma CTCs. Thus, further molecular and functional
studies aiming to investigate the role of ABCB5 in
melanoma CTCs, and interrogate CTC phenotypes during
disease evolution as well as throughout treatment will
unveil the relationship between ABCB5 and melanoma
progression.
The phenotypic and molecular heterogeneity of
melanoma CTCs, reported in this study, indicate that
the real heterogeneity of melanoma CTCs may still
be underestimated. Previous studies have detected
melanoma CTCs in 40% [11], 57% [16], 52% [10], 79%
[13] of patients, using CellSearch® (Janssen Diagnostics
LLC), isolation by size of epithelial tumour cells (ISET)
platform, multimarker flow cytometry and the herringbone
CTC-Chip, respectively. These rates are similar to the CTC
detection rates we observed of 54% (RT-PCR) and 43%
(immunostaining) in this study. However, it is likely that
differences in the CTC detection rates across these studies
may be attributed to the extraordinary heterogeneity of
melanoma CTCs both within and between patients [10].
Based on previous studies [10, 15, 16], we expect that not
all melanoma CTCs express the same markers. Therefore,
it is possible that the current markers used in downstream
approaches for CTC detection may constrain our ability
to detect the vast majority of melanoma CTC types.
Thus, studies aimed at the capture and study of the whole
range of melanoma CTCs to identify the real diversity of
these cells are urgently needed in order to pinpoint better
markers that minimise false negative results.
www.impactjournals.com/oncotarget

Challenges in the isolation and detection of CTCs,
particularly in melanoma, have hindered studies aiming
at unveiling the molecular mechanisms underlying
melanoma CTC biology relative to that of bulk tumour
cell biology. Nevertheless, although we did not analyse
patient-matched tumour samples in this study, we have
previously compared melanoma cell subpopulations
between patient matched blood and metastatic tumours
[10]. This revealed that cell populations expressing
melanoma initiating markers, such as ABCB5 and
RANK, are more common amongst CTCs than in the
matching tumour, suggesting a preferential selection for
certain tumour cell subtypes in the blood. Thus, further
investigation of CTC heterogeneity relative to tumour
diversity will provide a much clearer understanding
of the biology of CTCs and the metastatic process in
melanoma. The isolation of viable melanoma CTCs may
allow future biological characterisation through CTCderived cell cultures and xenotransplantation [18, 35–38].
Furthermore, research is required to validate the biomarker
utility of viable CTCs, as indicated previously by labeldependent methods [10–12, 16].
Ultimately, the isolation of viable, label-free
heterogeneous populations of melanoma CTCs using this
slanted enrichment device will facilitate future studies
aimed at unveiling the molecular mechanisms and biology
of melanoma CTCs and their role in melanoma metastasis
and response to therapy.

MATERIALS AND METHODS
Cell culture of melanoma cell lines
The melanoma cell lines 1205Lu, WM164, WM793
were kindly provided by Professor Meenhard Herlyn from
The Wistar Institute (Philadelphia, USA) and A2058,
SKMEL5 and UACC62 were originally obtained from the
American Type Culture Collection (ATCC, USA). Cell
lines were cultured in high-glucose Dulbecco’s modified
Eagle’s medium (DMEM) (Thermo Fisher Scientific)
supplemented with 10% foetal bovine serum (FBS)
(Thermo Fisher Scientific). The cultures were maintained
at 37°C in a humidified atmosphere containing 5% (v/v)
CO2 until 80% confluence. Cell lines were passaged
every 72 hours as per ATCC guidelines. Sub-confluent
monolayers were dissociated using 0.5% trypsin-EDTA
in 1X phosphate buffered saline (PBS) solution (137
mM NaCl, 10 mM Phosphate, 2.7 mM KCl, pH of 7.4)
(Thermo Fisher Scientific).
Flow cytometry was used to identify the different cell
sizes of melanoma cell lines. Cell lines with greater than
80% viability, were washed twice with FACS buffer (0.1%
bovine serum albumin, 100 mM EDTA, 10 mM HEPES,
phosphate-buffered saline) and immediately acquired in
a Gallios flow cytometer (Beckman Coulter). Cell sizes
were inferred from the respective forward scatter values
9
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for each cell line in an analysis performed using the Kaluza
Analysis Software (Beckman Coulter). Additionally, the
cell size of A2058 and SKMEL5 melanoma cell lines,
during 5 consecutive passages, was measured in a ViCELL XR cell counter (Beckman Coulter).

0.5% BSA/PBS solution through the slanted spiral device
at an input flow rate of 1700 μL min−1 controlled by a
syringe pump (PHD 2000, Harvard Apparatus).
The slanted spiral device allows recovery from two
outlets: one containing the recovered melanoma cells
(CTC outlet) and the other containing the remaining white
blood cells (waste outlet). To assess the recovery rate of
this spiral device, the cellular fraction from the CTC outlet
was transferred to a 48-well plate (Greiner Bio-One), and
centrifuged at 500 g for 5 mins. Recovery rates were
determined by counting the CellTracker™ red-labelled
cells in an inverted fluorescent microscope (Eclipse TiE, Nikon®) and the NIS-Elements High Content Analysis
software, version 4.2 (Nikon®). Purity of the slanted
enrichment was determined by counting the total number
of WBCs in the CTC fraction using a haemocytometer.
To increase the purity of the CTC fractions, we
evaluated the recovery rates and WBC background after
processing the sample twice through the slanted device
(2X slanted). For this, 50 labelled cells derived from
A2058 and SKMEL5 cell lines were spiked into 8 mL
of blood from 4 healthy donors. The cellular fraction of
the CTC outlet from the first round of slanted enrichment
was resuspended in a total volume of 6 mL of 0.5% BSA/
PBS solution and re-processed through the same washed
and primed slanted device at the same flow rate. Cell
Tracker™ red-labelled melanoma cells were counted as
above and WBCs were counted in the nucleated fraction
prior to enrichment, and in the ‘CTC’ fraction after 1st and
2nd rounds of enrichment.

Healthy volunteers and metastatic melanoma
patients
Twenty melanoma patients with metastatic disease,
at baseline, prior to clinical treatment with targeted
inhibitors or immunotherapies, were included in the
present study (Table 1). Healthy volunteers and melanoma
patients signed consent forms approved by the Human
Research Ethics Committees at Edith Cowan University
(No. 11543), Sir Charles Gairdner Hospital (No. 2013246) and South Metropolitan WA Health Service. For
each patient, two BD Vacutainer K2 EDTA tubes (BD
Biosciences) were collected and shipped to our research
laboratory for sample processing within 24 hours post
blood collection. The first five millilitres of blood were
discarded to avoid epithelial contamination.

Spiking of melanoma cell lines into blood of
healthy controls
The melanoma cell lines with the greatest
differential cell diameter, A2058 and SKMEL5, were
used to determine the efficiency of the slanted spiral
microfluidic device to isolate melanoma cells spiked
into blood from healthy donors. Cells were stained
with CellTracker™ Red CMTPX dye (Thermo Fisher
Scientific), and 1, 5, 10, 50 or 100 live-stained melanoma
cells were manually counted and spiked into 8 mL of
blood. Experiments were performed in triplicate for each
melanoma cell line.

Isolation of CTCs from metastatic melanoma
patients using the slanted spiral device
A total of 8 mL of blood were processed through
the slanted microfluidic device. CTCs were enriched
by processing the sample twice through the slanted
microfluidic device (2X slanted). After enrichment, RNA
was isolated using RNeasy Mini Kit (Qiagen) and stored
at -80°C until further use.

Recovery and purity of the slanted spiral
microfluidic device
Before processing the spiked blood samples through
the slanted device, blood samples were incubated with
red blood cell (RBC) lysis buffer (140 mM NH4Cl, 17
mM Tris, pH 7.65) for 10 mins at room temperature with
continuous gentle mixing. Lysed RBCs were subsequently
removed after centrifugation at 300 g for 5 min and the
nucleated cell fraction was washed twice with 20 mL of
PBS before resuspension into 16 mL (0.5x concentration)
of PBS supplemented with 0.5% bovine serum albumin
(0.5% BSA/PBS). Nucleated cells from blood were
processed through the slanted spiral microfluidic device as
described by Warkiani et al. [24] (Supplementary Figure
1). Briefly, the slanted chips were washed with ethanol
70% and PBS before being primed with 0.5% BSA/PBS
solution prior to sample processing. Melanoma cells were
isolated by processing 16 mL of the nucleated cells in
www.impactjournals.com/oncotarget

Detection of melanoma CTCs by flow cytometry
An aliquot of 8 mL of blood was processed by
multimarker flow cytometry to confirm the presence
of CTCs after microfluidic enrichment, as described by
Gray et al. [10]. For this, blood samples were processed
once through the slanted spiral device (1X slanted)
and the enriched CTC fraction was then assessed for
melanoma CTC subpopulations using our multimarker
flow cytometry assay and the same gating strategies as
previously described [10]. A total of 1 x 105 WBCs from
the waste outlet of the slanted device, were used as an
isotype control for CTCs from the same patient sample,
enriched via the device. The total and subpopulationspecific CTC counts were compared pre- and post10
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enrichment for every patient. For this, two additional
aliquots of 8 mL of blood, one as an isotype control and
the other as a pre-enrichment test sample, were collected
and processed at the same time and from the same patient
as the samples used for microfluidic enrichment.

with 0.2% TX-100/PBS solution, and incubated with a
donkey anti-rabbit IgG antibody conjugated to Alexa
Fluor® 488 dye (Abcam) in blocking buffer. Finally, cells
were mounted using ProLong® Gold Antifade Mountant
with DAPI (4',6-diamidino-2-phenylindole) nuclear stain
reagent (Thermo Fisher Scientific). Slides were stored
at 4°C, visualised and scanned using the Eclipse Ti-E
inverted fluorescent microscope (Nikon®). Stained cells
were analysed using the NIS-Elements High Content
Analysis software, version 4.2 (Nikon®) by two trained
researchers. Background subtraction parameters for each
marker, derived from immunostaining of A2058 melanoma
cells spiked into WBC fractions, were stringently applied
to all stained slides from patients’ CTC-enriched samples.
After background subtraction, signal for each fluorescent
dye was also adjusted to enhance the staining for each
marker and parameters were applied to all stained
slides. Only cells with confirmed positive staining, after
background subtraction, for either MCSP, MEL or both
and negative for the leukocytic marker CD45 were deemed
as melanoma CTCs by consensus of multiple authors.

Gene expression assay to confirm CTC isolation
As previously described by Reid et al. [40], the
expression of a panel of 5 melanoma-specific genes were
assessed to confirm the presence of melanoma CTCs after
slanted enrichment. Briefly, RNA (6 μL) isolated from
cells from the enriched ‘CTC fraction’, for both spiked
samples and patient blood, was reverse transcribed to
cDNA using SuperScript® VILO™ master mix (Thermo
Fisher Scientific, US) in a 10 μL final volume reaction.
Subsequently, MLANA, TYR, MAGEA3, ABCB5 and
PAX3 genes were preamplified in a reaction containing
5 μL of input cDNA, 0.2X of a mixture of the TaqMan
assays targeting these genes and the TaqMan® PreAmp
Master Mix (Thermo Fisher Scientific). Expression of
each of the 5 genes was then determined by qPCR of the
preamplified cDNA using commercially designed TaqMan
Gene Expression assays for each target gene. The 18S
rRNA gene was used as an endogenous control. Cycling
conditions and fluorescence detection of these PCR
reactions were carried out in a ViiA™ 7 Real-Time PCR
system (Thermo Fisher Scientific) [40]. Expression values
were represented as the reciprocal Ct value for each target
gene and plotted in a heatmap using the HeatMapViewer
module (version 13.9; Broad Institute) at the GenePattern
platform [57]. RNA isolated from cells in the CTC outlet
after processing the blood of healthy individuals and from
a sample spiked with 20 A2058 cells were included as
negative and positive controls, respectively.

Statistical analysis
A two-tailed independent t-test was used to compare
the mean cell diameters of A2058 and SKMEL cells.
One-way ANOVA analyses were used to find statistical
differences in the recovery rates for A2058 and SKMEL5
cell lines between different spiked concentrations after
1X slanted enrichment. Similarly, one-way ANOVA was
used to determine the efficiency of the slanted device to
deplete WBCs after the second round of enrichment with
this device processing blood samples from controls and
patients. Statistical significance was reached with a P
<0.05.

Immunofluorescence staining
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Immediately after the second round of slanted
enrichment, cells within the ‘CTC-enriched fraction’ were
fixed by 10 min incubation with 4% Paraformaldehyde
(PFA) and subsequently cytospun (Cytospin™ 4, Thermo
Fisher Scientific) onto a glass slide at 2000 rpm for 5
mins. Cells were again fixed with 4% PFA for 10 mins,
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normal donkey serum (NDS), 3% bovine serum albumin
(BSA) and 0.2% Triton X-100 (TX-100) in PBS for 15
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rabbit anti-MLANA/MART1 (clone EP1422Y, Abcam),
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